HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.80215
+0.0016 (0.19%)
Nov 13, 2026, 1:46 PM EST - Market open
HCW Biologics Revenue
HCW Biologics had revenue of $135.57K in the quarter ending June 30, 2026, with 1,969.74% growth. This brings the company's total for the last twelve months to $6.72M, up 707.02% year-over-year. In the year 2025, HCW Biologics had annual revenue of $54.23K, down -97.89%. That makes HCW Biologics the 38,968th largest company in the world by revenue and 5,127th in the United States.
Revenue (ttm)
$6.72M
Revenue Growth
+707.02%
P/S Ratio
0.27
Revenue / Employee
$192,034
Employees
35
Market Cap
1.79M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.23K | -2.51M | -97.89% |
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 4.31M |
| 60 Degrees Pharmaceuticals | 1.21M |
| BioRestorative Therapies | 357.87K |
| VivoSim Labs | 112.00K |
| Jupiter Neurosciences | 64.69K |
HCWB News
- 7 days ago - HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer - GlobeNewsWire
- 7 days ago - HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting - GlobeNewsWire
- 8 days ago - HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing - GlobeNewsWire
- 5 weeks ago - HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors - GlobeNewsWire
- 5 weeks ago - HCW Biologics registers to sell 1.81M shares of common stock for holders - TheFly
- 6 weeks ago - HCW Biologics Registration statement: Registration filing - Filings
- 6 weeks ago - HCW Biologics Proxy statement: Proxy filing - Filings
- 7 weeks ago - HCW Biologics prices 903,614 units at $1.6599 in private placement - TheFly